Charles River Laboratories

Historical price data

Charles River Laboratories operates as a foundational partner in the biopharmaceutical ecosystem, offering an integrated suite of services spanning research models, discovery, safety assessment, and manufacturing support. The company has established itself as a bellwether for industry R&D activity, with a notable 80% of FDA-approved drugs over the past five years having utilized its services. Its strategy focuses on expanding capabilities in high-growth areas like cell and gene therapy, investing in New Approach Methodologies (NAMs) to reduce animal testing, and leveraging its global scale to provide end-to-end solutions that streamline client pathways to regulatory submission.

An integrated suite of services and technologies spanning research models (GEMS), integrated drug discovery, specialized platforms (Retrogenix, SAMiRNA, Porcilon), IND-enabling safety assessment, New Approach Methodologies (NAMs), and biologics & cell/gene therapy CDMO manufacturing.

Charles River competes with large, full-service CROs like Labcorp and IQVIA in discovery/preclinical, specialized CDMOs like Lonza in manufacturing, and niche players in research models. Its key differentiators are its unique integrated model from models to CDMO, global scale, and a strong regulatory track record supporting a vast majority of recent drug approvals.